{"prompt": "['2016N293064_03', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Reproductive toxicology (Embryofetal', 'In a rat embryofetal development study, an', 'As danirixin HBr has shown the potential to', 'development)', 'oral dose of 300 mg/kg/day resulted in fetal', 'cause fetal malformations, danirixin or', 'skeletal variations in the skull (reductions in', 'danirixin HBr must not be administered to', 'ossification). There were no test article-', 'pregnant women or nursing mothers.', 'related effects on numbers of corpora lutea,', 'Women of childbearing potential should', 'implantations, embryofetal survival,', 'only be included in clinical trials with the', 'placental morphology, gravid uterine', 'use of appropriate precautions against', 'weight, sex ratio, fetal body weight, or fetal', 'pregnancy.', 'morphology (external and visceral).', 'Male participants with female partners of', 'child-bearing potential must comply with', 'the contraception requirements.', 'Study Procedures', 'None', 'Other', 'Not applicable', '96']['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Amended text:', '3.3.1 Risk Assessment', 'Investigational Product (IP) [Danirixin, GSK1325756', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Testicular effects and male fertility', 'The most sensitive species is the rat.', 'Standard safety monitoring will be', 'Testicular effects present at doses >150', 'employed.', 'mg/kg/day in the rat include spermatid', 'degeneration, seminiferous tubular', 'The potential risk of testicular injury has', 'degeneration and secondary epididymal', 'been conveyed in the informed consent.', 'changes, including oligo/aspermia and/or', 'epididymal intratubular cellular debris. The', 'PK modelling predicts that in a participant', 'no observed adverse effect level (NOAEL)', 'receiving 35 mg BID of the HBr salt, the', 'in this study, based on the microscopic', 'risk of exposure exceeding the 2-fold', 'findings in the testis, was 50 mg/kg/day for', 'margin for AUC(0-24) for the NOAEL of', 'male rats. The systemic exposure margins', 'testicular effects is low.', 'for the NOAEL for testicular effects in the', 'rat is 7.3-fold for an oral clinical dose of 50', 'mg BID free base tablet.', 'The testicular effects seen in the rat have', 'also been shown to directly impact on male', 'fertility and the NOAEL for these', 'reproductive effects was 100 mg/kg/day.', 'Refer to IB Section 4.4 for full details', 'No adverse events related to testicular', 'effects have been observed in clinical', '97']['2016N293064_03', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'studies to date.', 'Impairment of host defense.', 'Host defense has not been studied directly', 'Monitoring of neutrophil count.', 'in nonclinical studies. However, data in', 'nonclinical species have not identified an', 'Stopping criteria: in participants with a', 'increased risk of infection with danirixin.', 'confirmed absolute neutrophil count < 0.5 X', 'Nonclinical studies in mice and ferrets with', '109/L product will be discontinued and', 'two CXCR2 antagonists in the same', 'neutrophil count will be monitored until', 'chemical class as danirixin have not shown', 'return to normal. Participants may be', 'an increase in infections in challenge', 'restarted on study treatment as detailed in', 'models (e.g., influenza viral load).', 'Appendix 9.', 'Secondary bacterial infections after viral', 'infection have not been directly evaluated in', 'Ongoing assessment of AE/SAEs related to', 'nonclinical studies.', 'infection.', 'The data from clinical studies including', 'Closely monitor, collect information on and', 'healthy participants, COPD and influenza', 'characterize infection events such as', 'patients thus far show no evidence that', 'pneumonia, and use adjudication as', 'participants taking danirixin have an', 'appropriate.', 'increased infection rate compared with', 'participants taking placebo.', 'Neutropenia has been reported in clinical', 'trials of other CXCR2 antagonists. No', 'instances of neutropenia have been reported', 'in nonclinical studies with danirixin. In', 'healthy volunteer studies and a phase 2a', '98']\n\n###\n\n", "completion": "END"}